EUVIMEDEUVIMED entdecken
Crossref

Conundrum of low hormone receptor-positive breast cancer

Dilip Harindran Vallathol, Arun R Warrier

Asian Journal of Oncology · 02.11.2026 · 12 · 35

DOI: 10.25259/asjo_100_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Oncology, online erschienen am 02.11.2026. Verfasst von Dilip Harindran Vallathol und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor-low (HR-low) breast cancer, defined by ASCO/CAP guidelines as displaying 1% to 10% estrogen and/or progesterone receptor expression, presents a significant clinical dilemma. Accounting for approximately 7% of cases, this cohort is characteristically associated with younger patients, high-grade tumors, elevated Ki-67 indices, and distinct biological heterogeneity. Clinically, HR-low tumors exhibit a profound paradox: while standard guidelines recommend managing them as luminal-type disease, their molecular features, high tumor-infiltrating lymphocyte counts, and PD-L1 expression profiles closely mirror basal-like, triple-negative breast cancer (TNBC). Pathological identification remains heavily confounded by subjective interpretation and preanalytical testing variations. Therapeutic outcomes further highlight this dual identity; HR-low tumors achieve high pathological complete response (pCR) rates to neoadjuvant chemotherapy and immunotherapy protocols (such as the KEYNOTE-522 regimen) that are comparable to TNBC, yet they experience worse overall survival than strongly HR-positive cancers. Conversely, large-scale data confirms a distinct overall survival benefit from adjuvant endocrine therapy, though extending this treatment beyond three years yields no additional survival advantage. Ongoing clinical uncertainty persists regarding their inclusion in major trials. Managing HR-low breast cancer requires transitioning away from rigid immunohistochemical thresholds toward a nuanced, personalized approach utilizing molecular profiling to accurately identify patient subsets most likely to benefit from targeted endocrine or immunotherapeutic strategies.

Zitieren

APA

Vallathol, D. H., & Warrier, A. R. (2026). Conundrum of low hormone receptor-positive breast cancer. Asian Journal of Oncology, 12, 35. https://doi.org/10.25259/asjo_100_2025

Vancouver

Vallathol DH, Warrier AR. Conundrum of low hormone receptor-positive breast cancer. Asian Journal of Oncology. 2026;12:35. doi:10.25259/asjo_100_2025

BibTeX
@article{Vallathol2026,
  author = {Vallathol, Dilip Harindran and Warrier, Arun R},
  title = {Conundrum of low hormone receptor-positive breast cancer},
  journal = {Asian Journal of Oncology},
  year = {2026},
  volume = {12},
  pages = {35},
  doi = {10.25259/asjo_100_2025}
}
Kostenlos starten →